Navigation Links
BioXcel Launches Its Flagship Product, PharmGPS™
Date:4/22/2013

Branford, CT (PRWEB) April 22, 2013

BioXcel Corporation, coinciding with the BIO International 2013 Convention in Chicago, announced the launch of PharmGPS™, a “first-in-class,” dynamic analytics platform with customizable apps, built to address complex investment decisions across the biopharmaceutical industry stakeholder value-chain.

“Decision making and knowledge management paradigms are fragmented and becoming increasingly complex with the explosion of data and a rapidly evolving healthcare ecosystem,” said Dr. Vimal Mehta, BioXcel’s Chairman. “PharmGPS™ provides an innovative solution to revolutionize decision making with a unified platform for actionable decisions thereby optimizing investments and enhancing the probability of success.

PharmGPS™ is a disease-area focused, analytics engine encompassing all major and specialty therapeutic areas. Using a patient-centric approach, PharmGPS™ assesses each disease indication for the best window of commercial opportunity, dynamic probability of technical and regulatory success, forecasting, and scenario analysis. This applies to both in-market and pipeline drugs, satisfying the future standard of care in each disease indication/segment. “BioXcel’s long-term commitment to developing PharmGPSTM has been supported by multiple clients working to meet patient needs,” said Dr. Krishnan Nandabalan, BioXcel’s President & CEO. “We are vigorously expanding current indications and commercializing this exciting new product to a wide biopharmaceutical audience.”

The platform is built on several years’ experience, deep domain expertise, commercially validated frameworks, and proprietary processes for generating insights and recommendations. The analytics engine operates on dynamic specialized data sets, each structured by experts from medical, clinical, scientific, commercial, and intellectual property disciplines. It also allows stakeholders to leverage intern
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
2. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
3. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
4. Ambry Genetics Launches Illumina MiSeq Next-Gen Sequencing Services
5. Neogen Launches Fully Quantitative Lateral Flow Test for DON
6. Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
7. iHealth Lab Launches Personalized Web Portal to Store Your Vitals
8. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
9. Upsher-Smith Launches B-Nexa® Prescription Prenatal Vitamin With B Vitamins and Ginger for Nausea and Vomiting of Pregnancy
10. bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation
11. ERT Launches New Website to Support Significant Commercial Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2015 TapImmune, Inc. (OTCQB: TPIV), a clinical ... reached an agreement whereby the institutional investors will have ... provide the Company up to $4.93M in near term ... statement. Under the restructured terms and subject to certain ... which could result in a larger influx of capital ...
(Date:6/2/2015)... , June 02, 2015 Research and ... the "Bioburden Testing Market by Product , Test, ... report to their offering. The bioburden testing ... from $354.4 Million in 2014, growing at a CAGR ... basis of products, the microbial limit testing market is ...
(Date:6/2/2015)... , June 2, 2015 Meet ... Emotion Scanner. Scan & Read People. Analyze emotions and ... ART Concepts, including the very first Responsive-RPG: "The Eye: ... , , , , ... and truly affect your inner feelings - and those ...
(Date:6/2/2015)... June 2, 2015   Y-Prime, Inc ., ... BIO Exhibition 2015 in Philadelphia ... largest biotechnology gathering, allows influential decision makers from ... they can evaluate emerging technologies such as YPrime. ... in the design, implementation and management of Interactive ...
Breaking Biology Technology:TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3Bioburden Testing Market 2015 - Global Forecasts to 2019 2ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 2ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 3YPrime at BIO Exhibition in Philadelphia and DIA in Washington DC during the month of June 2
... The secret of a successful sandcastle could aid the revival ... by Durham University. Researchers, led by experts at Durham,s ... strength of rammed earth, which is growing in popularity as ... a little water to stand up, the Durham engineers found ...
... 2 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ... Phase 3 clinical study of fidaxomicin in patients with ... by clinical investigator, Mark A. Miller, M.D., at the ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ) , , ...
... 2 Document sharing inefficiencies in clinical trials cost investigative ... recent online poll by IntraLinks(R), the leading provider of critical ... document-related administrative duties and repetitive requests for information as significant ... of the polling results include: , , ...
Cached Biology Technology:Secret of sandcastle construction could help revive ancient building technique, researchers say 2Secret of sandcastle construction could help revive ancient building technique, researchers say 3Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 2Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 3Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 4Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI 5Document Management Inefficiencies Cost Clinical Study Sites Time, Money 2
(Date:5/21/2015)... , May 21, 2015 ... Imaging Market by Solutions (Hardware, Software, Services), by Applications ... & others), by End-Users (Military & Defense & ... MarketsandMarkets, Thermal Imaging Market is expected to grow ... by 2020, at a Compound Annual Growth Rate ...
(Date:5/20/2015)... May 20, 2015 NXT-ID, Inc. (NASDAQ: ... wholly owned subsidiary, 3D-ID LLC, a company engaged in ... for the biometrics technology portion of the recently awarded ... the Department of the Army. 3D-ID LLC ... for government, law enforcement and security agencies. ...
(Date:5/19/2015)... DUBLIN , May 19, 2015 /PRNewswire/ ... ) has announced the addition of the  ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A ... provides an in-depth analysis of the current ... introduction of gene-based tests, their working principles ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... study in the September 6 issue of the Journal of ... an important ciliary protein, CEP290. The results could be applied ... Mutations in human CEP290 cause cilia-related disorders that range in ... known to cause Meckel syndrome, Joubert syndrome, and NPHPthe most ...
... bacterial cells that act in their own interests ... can actually reduce the severity of infection. ... could be exploited to treat antibiotic-resistant infections, according ... General Microbiology,s autumn meeting today. Bacteria work ...
... Society is delighted to announce its 2011 Society Fellows. ... in science, contributions to the expansion of the field ... Fellows will be honored at the Awards Ceremony during ... 7, 2011 at the Baltimore Convention Center in Baltimore, ...
Cached Biology News:Backstabbing bacteria: A new treatment for infection? 2
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... This system uses the Adept CE 4100 ... Ultra-Fast Scanning UV/Visible detector for added flexibility and ... a trustworthy alternative to a photodiode array detection ... one detector is required for method development and ...
... number is a new product number, ... number. If showing no availability yet, ... number (E6152) or contact customer service ... diam. 11.25 6.40 in. ...
... Analysis of large numbers of samples may be ... requires minimum operator attention. System control and ... interface CE 4900. The elegant, powerful and ... XP and Windows 98 and 2000., The supplied ...
Biology Products: